Orlovic-Nachwuchsfonds Innovative Kardiologie
Who can apply: Not specified in the provided content. The program is targeted at innovative cardiology research and young researchers.
Dr. Marija Orlovic Stiftung für medizinische Forschung supports small, highly targeted medical research projects in Germany, with a clear emphasis on innovative cardiology. Its stated priorities center on systemische Viruserkrankungen des Herzens, especially virus-related myocarditis, as well as coronary heart disease in insulin-dependent type II diabetes, with an emphasis on diagnostics and treatment methods. The foundation appears to favor early-career researchers and university-affiliated clinical cardiology teams working on translational, clinically relevant projects.
Small annual program funding around €10,000, likely distributed through a targeted award or Nachwuchsfonds. Funding appears to be program-based and selective, with no evidence of an open broad grants process beyond the specific call in Germany.
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Monitor the Deutsches Stiftungszentrum listings for the Orlovic-Nachwuchsfonds call and apply in German if possible. Proposals should be tightly aligned with innovative cardiology, especially viral myocarditis, cardiac diagnostics, or coronary disease in insulin-dependent diabetes, and should highlight clinical relevance and early-career investigator involvement.
Current and upcoming funding from Dr. Marija Orlovic Stiftung für medizinische Forschung that your nonprofit may be able to apply for.
Who can apply: Not specified in the provided content. The program is targeted at innovative cardiology research and young researchers.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.